Community-acquired pneumonia: recent guidelines for therapy.

Title

Community-acquired pneumonia: recent guidelines for therapy.

Creator

File T M Jr

Publisher

Journal of Respiratory Diseases

Date

1999
1999-08

Description

The Infectious Diseases Society of America advocates using pathogen-directed therapy whenever possible to help reduce the emergence of drug resistance. Options for empiric therapy for outpatients include a macrolide, a new fluoroquinolone with enhanced activity against Streptococcus pneumoniae, and doxycycline. A newer fluoroquinolone is an appropriate option when drug-resistant S pneumoniae is a concern. For patients requiring hospitalization in a general ward, the preferred options are a beta-lactam plus a macrolide or a new fluoroquinolone with activity against S pneumoniae.

Subject

Pneumonia – Drug Therapy; Community-Acquired Infections – Drug Therapy; Pneumonia – Microbiology; Community-Acquired Infections – Microbiology

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

534–541

Issue

8

Volume

20

Citation

File T M Jr, “Community-acquired pneumonia: recent guidelines for therapy.,” NEOMED Bibliography Database, accessed May 26, 2022, https://neomed.omeka.net/items/show/6133.

Social Bookmarking